SeqWell Inc.

SeqWell Inc. specializes in innovative next-generation sequencing (NGS) library preparation solutions, enhancing genomics research efficiency and accuracy with advanced technologies and high-throughput applications. SeqWell Inc. was founded in 2014 in Beverly, US, focusing on next-generation sequencing library preparation.

The company has raised a total of USD 7. 00 mn through a SERIES C round led by Codexis, Inc. , with participation from BroadOak Capital Partners and Research Corporation Technologies. The most recent funding round occurred in April 2022, and SeqWell currently holds a valuation of USD 57.

52 mn. The founders, Jack Leonard and Joe Mellor, have backgrounds in innovative scientific technologies. SeqWell specializes in next-generation sequencing (NGS) library preparation solutions that simplify and accelerate workflows for genomics research. Their flagship products, such as the TnX and plexWell LP 384 kits, utilize innovative tagmentation-based workflows designed for high-throughput applications.

These products facilitate the preparation of NGS libraries from hundreds to thousands of samples with improved consistency, uniformity of coverage, and increased library yield. The technology caters to a diverse clientele, including research institutions, genomics centers, and laboratories focusing on various species and applications, ranging from conservation genomics to infectious disease monitoring. SeqWell serves customers primarily in North America, with significant engagement in markets across Europe and Asia, offering scalable solutions that adapt to specific research needs. The revenue model for SeqWell is built around direct sales to research institutions and laboratories, focusing on B2B transactions.

Clients purchase products such as the TnX and plexWell kits, which are offered as part of their library prep technology portfolio. The pricing structure for these products is designed for bulk purchases, catering to high-throughput research environments. Additionally, SeqWell may engage in partnerships with genomic service providers, enhancing their market reach and facilitating access to their technologies. This business model enables SeqWell to maintain a competitive edge in the rapidly evolving genomics market, while delivering significant value to its customers through streamlined and efficient library preparation processes.

In April 2022, SeqWell Inc. raised USD 7. 00 mn in SERIES C funding to accelerate the commercialization of its genomics workflow solutions. The company plans to expand its product offerings with new technologies designed to enhance library preparation efficiency.

SeqWell also aims to extend its market presence in Europe and Asia by the end of 2023, focusing on establishing partnerships with additional genomic service providers. The funding will be instrumental in supporting these initiatives, allowing SeqWell to enhance its product development and marketing efforts.